Keywords: ThromboGenics, Jetrea, US launch, VMA, vitreomacular adhesion, Sales and earings forecasts, Enterprise value, Edison Investment Research

ThromboGenics starts Jetrea roll-out in USA

Article | 15 January 2013

With the launch of its Jetrea (ocriplasmin) in the USA imminent, Belgian drugmaker ThromboGenics (Euronext Brussels: THR) has seen upward ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

ThromboGenics

Go to company listing

Related Drugs

Jetrea

Go to drug listing